STM JOURNALS

Research & Reviews: A Journal of
Biotechnology

https://journals.stmjournals.com/rrjobt/

ISSN: 2231-3826 (Online)
ISSN: 2347-7245 (Print)
Volume 16, Issue 1, 2026
January–April
DOI (Journal): 10.37591/RRJoBT

Review RRJoBT

Metagenome-Informed Engineering of Monoclonal Antibodies: Mining Microbial Immunoglobulin-Like Domains for Ultra-Stable Therapeutics

Atul Khajuria[1,*], Ashish Kumar[2]

Abstract

Metagenome-informed engineering represents an emerging strategy for improving the stability and functionality of monoclonal antibodies (mAbs) by leveraging the vast diversity of microbial immunoglobulin-like (Ig-like) domains. These domains, derived from uncultured bacteria and bacteriophages, exhibit exceptional thermostability, protease resistance, and structural resilience due to adaptation to extreme environments.. This review highlights advances in metagenomic mining, structural characterization, and protein engineering that enable the integration of microbial Ig-like scaffolds into antibody frameworks. Key engineering approaches, including CDR grafting, domain fusion, and de novo design, are discussed alongside preclinical validation methods and stability assays. The therapeutic potential of ultra-stable mAbs across oncology, infectious diseases, and autoimmune disorders is examined, with emphasis on improved pharmacokinetics and manufacturability. Challenges – such as immunogenicity and regulatory considerations – are also addressed, along with strategies for mitigation. Finally, the integration of artificial intelligence and synthetic biology is explored as a future direction for accelerating antibody design. Overall, metagenome-informed antibody engineering offers a transformative pathway toward developing next-generation biologics with enhanced stability, reduced cost, and broader global accessibility.

Keywords: Metagenomics, monoclonal antibodies, immunoglobulin-like domains, protein engineering, thermostability, antibody stability, microbial scaffolds, biologics, Fc engineering, synthetic biology

INTRODUCTION

Monoclonal Antibody Production Flowchart

Metagenome-informed engineering leverages vast microbial genetic diversity to identify immunoglobulin-like (Ig-like) domains for enhancing monoclonal antibody (mAb) stability and therapeutic potential. Microbial Ig-like domains, mined from uncultured bacteria and phages, offer scaffolds with exceptional thermostability due to evolutionary adaptations in extreme environments. This approach promises ultra-stable proteins resistant to aggregation and proteolysis, addressing key limitations in current mAb therapies.[1-5]

***Author for Correspondence**
Atul Khajuria
E-mail: atulkhajuria83@gmail.com

[1]Dean, Department of Allied & Healthcare Sciences,, Rayat Bahra Professional University, Hoshiarpur, Punjab, India
[2]Assistant Professor, Department of Allied & Healthcare Sciences,, Rayat Bahra Professional University, Hoshiarpur, Punjab, India

Received Date: March 19, 2026
Accepted Date: April 27, 2026
Published Date: May 07, 2026

Citation: Atul Khajuria, Ashish Kumar. Metagenome-Informed Engineering of Monoclonal Antibodies: Mining Microbial Immunoglobulin-Like Domains for Ultra-Stable Therapeutics. Research & Reviews: A Journal of Biotechnology. 2026; 16(1): 70–83p.

Monoclonal antibodies (mAbs) represent a cornerstone of modern therapeutics, with over 100 approved agents targeting cancers, autoimmune disorders, and infectious diseases [6-11]. However, inherent instability – manifesting as aggregation, poor solubility, and short half-lives – limits their efficacy, manufacturability, and cost-effectiveness [12, 13]. Metagenome-informed engineering addresses these

by mining immunoglobulin-like (Ig-like) domains from microbial metagenomes, yielding scaffolds with superior thermostability derived from evolutionary pressures in diverse microbiomes.[14-20]

This review synthesizes advances in metagenomic discovery, structural biology, and protein engineering, proposing a pipeline for ultra-stable therapeutic proteins. Microbial Ig-like domains, abundant yet underutilized, offer β-barrel architectures resilient to extremes, paving the way for next-generation biologics.

Monoclonal Antibody Production Flowchart (Conceptual Pictorial Overview)

[Antigen Selection]
↓
[Immunization / B-cell Isolation]
↓
[Hybridoma / Single B-cell Technology]
↓
[Screening & Clone Selection]
↓
[Gene Sequencing & Cloning]
↓
[Expression System (CHO / *E. coli* / Yeast)]
↓
[Purification (Protein A/G, Chromatography)]
↓
[Characterization (Affinity, Stability)]
↓
[Engineering (Fc/Fab Optimization)]
↓
[Preclinical Testing → Clinical Trials]

"This schematic *Flowchart* provides a simplified yet comprehensive overview of monoclonal antibody development from antigen selection to clinical translation"[21]

MICROBIAL IG-LIKE DOMAINS

Microbes harbor diverse Ig-like domains in adhesins, chaperones, and secretion systems, structurally mimicking eukaryotic immunoglobulins but evolved for prokaryotic functions like adhesion and stability. Examples include PapD in *Escherichia coli* and domains in bacteriophages, forming β-sandwich folds resilient to harsh conditions [22, 24]. Metagenomics uncovers novel variants from uncultured microbiomes, bypassing cultivation biases [24-28].

These domains stabilize cargo proteins during type IX secretion and conjugation, preventing degradation by proteases like HtrA. Bioinformatics reveals homologs across Gram-positive pathogens, suggesting broad utility for engineering [29-33].

MICROBIAL IG-LIKE DOMAINS: EVOLUTIONARY DIVERSITY

Immunoglobulin-like domains, characterized by 70–110 residue β-sandwich folds, permeate eukaryotic immunity but trace origins to prokaryotes [34]. In bacteria, they function in adhesion (e.g., intimin-like domains), secretion (autotransporters), and phage-host interactions [21].

Phages encode Ig-like domains in tail fibers for host recognition, displaying pH- and heat-tolerance exceeding mammalian counterparts [21]. Enterobacterial PapD-like chaperins stabilize pilus subunits, resisting periplasmic proteases [22].

Gram-positive Firmicutes feature IgI3 domains in collagen adhesins, with melting temperatures exceeding 80°C.[Table:1,2]

Key microbial Ig-Like domains are as depicted in Table 1.

Table 1. Key microbial Ig-like domain families.

Family	Organism/source	Function	Stability features	References
PapD-like	*E. coli*	Pilus chaperone	Protease resistance	[22]
IgI3	Gram+ pathogens	Adhesin	>80°C Tm	[34]
Phage tail Ig	Bacteriophages	Host binding	pH 2–12 tolerance	[21]
Spy0128-like	Streptococcus	Collagen anchor	GdnHCl >4M	[23]
DEv-Ig	Viral metagenomes	Capsid stabilizer	Hyperstable	[34]

METAGENOMIC MINING STRATEGIES

Metagenomic sequencing generates reference-free protein families from environmental samples, identifying functional Ig-like domains via computational clustering [28]. Tools, like MIG-Seq profile IgA-coated microbes, link gene content to immune recognition for predictive modeling [27]. Ultra-sensitive metaproteomics (uMetaP) complements this by quantifying expressed proteins [25].

Bioinformatics pipelines scan for Ig-like folds using structural alignment tools such as DALI and PDBeFOLD. Directed evolution and phage display refine candidates for antibody fusion [4].

Table 2. Metagenomic platforms for Ig-like mining.

Platform	Resolution	Sample types	Yield	References
Shotgun MetaG	Gene clusters	Soil/Gut/Ocean	10^4–10^5	[25]
MIG-Seq	Strain-level	Mucosal	500+	[27]
uMetaP	Proteoform	Injury models	10^3	[28]
Long-read MAGs	Complete scaffolds	Extreme environments	High	[25]

STRUCTURAL FEATURES CONFERRING STABILITY

Ultra-stability arises from optimized topologies: Greek-key β-barrels with buried aromatics and salt-bridges replacing disulfides. Microbial domains often lack cysteines, relying instead on hydrophobic packing [29]. Molecular dynamics simulations demonstrate reduced conformational flexibility compared to human VH domains, contributing to enhanced thermal resistance.

At the molecular level, microbial Ig-like domains exhibit a highly conserved β-sandwich architecture, typically composed of two antiparallel β-sheets arranged in a compact fold [34]. This topology minimizes solvent exposure of hydrophobic residues, thereby reducing the thermodynamic drive for unfolding and aggregation [29]. Unlike mammalian immunoglobulins, which often depend on disulfide bonds for structural integrity, microbial Ig-like domains achieve comparable or superior stability through disulfide-independent stabilization mechanisms, making them particularly suitable for reducing environments such as the cytoplasm or industrial bioprocessing conditions [30].

A key determinant of stability is the presence of densely packed hydrophobic cores, often enriched with aromatic residues such as tryptophan, tyrosine, and phenylalanine. These residues participate in π–π stacking interactions and van der Waals forces, forming a rigid internal scaffold [29]. Such aromatic clusters significantly increase the folding free energy barrier, thereby enhancing resistance to thermal and chemical denaturation. In addition, cation–π interactions between positively charged residues (e.g., lysine, arginine) and aromatic side chains further stabilize the fold, a feature frequently observed in extremophilic microbial proteins [23].

Electrostatic interactions also play a crucial role. Microbial Ig-like domains often contain extensive salt-bridge networks, particularly at loop regions and β-strand interfaces [34]. These salt bridges not only stabilize local conformations but also contribute to global fold rigidity by anchoring flexible regions. Compared to human VH domains, where loop flexibility is essential for antigen binding, microbial domains exhibit shortened and structurally constrained loops, reducing conformational entropy and enhancing thermostability [24].

Another important structural adaptation is the reduction in loop length and flexibility, which directly correlates with decreased entropy in the unfolded state. This entropy minimization leads to a higher melting temperature (Tm) and improved resistance to unfolding [29]. Proline residues are frequently enriched in loop regions, introducing conformational rigidity due to their cyclic structure, thereby stabilizing β-turns and preventing unwanted structural fluctuations [34].

Hydrogen bonding networks within β-sheets are also optimized in microbial Ig-like domains. These domains exhibit highly cooperative hydrogen bond patterns, often reinforced by backbone-backbone interactions that extend across β-strands [29]. This cooperative bonding enhances structural resilience under extreme conditions such as high temperature, pH variation, and denaturant exposure [21].

Insights from molecular dynamics (MD) simulations further support these observations. Comparative MD analyses reveal that microbial Ig-like domains have lower root mean square fluctuation (RMSF) values, particularly in loop regions, indicating reduced atomic mobility [30]. Additionally, these domains display higher folding cooperativity and slower unfolding kinetics, suggesting a kinetically trapped, highly stable conformation [24]. Energy landscape analysis indicates a deeper and narrower global minimum, reflecting a strongly favored native state with limited conformational heterogeneity [29].

Furthermore, many microbial Ig-like domains exhibit enhanced resistance to chaotropic agents such as guanidinium hydrochloride (GdnHCl) and urea. This resistance is attributed to tightly packed cores and reduced solvent-accessible surface areas, which limit the penetration of denaturants into the protein interior [29, 30]. Such features are particularly advantageous for therapeutic antibodies, which must maintain stability during storage, transport, and administration [13].

From an evolutionary perspective, these stability-enhancing features are likely driven by adaptation to extreme environmental conditions, including high temperature, osmotic stress, and protease-rich niches [28]. As a result, microbial Ig-like domains represent naturally optimized scaffolds that can be directly harnessed or further engineered for therapeutic applications [23].

Collectively, the combination of hydrophobic core optimization, electrostatic stabilization, loop minimization, and cooperative hydrogen bonding defines the exceptional stability of microbial Ig-like domains. These structural principles provide a robust framework for engineering next-generation monoclonal antibodies with enhanced thermal tolerance, reduced aggregation propensity, and improved manufacturability [10, 29].[Table:3]

Table 3. Stability determinants in microbial Ig-like domains.

Feature	Mechanism	Tm gain (°C)	Example	References
Aromatic core	Hydrophobic burial	+20–30	Phage Ig	[29]
Salt-bridges	Loop stabilization	+15	IgI3	[24]
Proline kinks	Turn rigidity	+10	PapD	[23]
Reduced loops	Entropy reduction	+25	DEv-Ig	[29]

ENGINEERING ULTRA-STABLE MABS

Ig-like domains graft onto mAb frameworks via CDR replacement or fusion, enhancing β-sheet cross-links for thermostability. De novo designs using computational tools yield scaffolds with confirmed structures [24]. Fc engineering enhances effector functions such as ADCC and CDC [17, 18].

Engineering ultra-stable monoclonal antibodies involves the strategic integration of microbial immunoglobulin-like (Ig-like) domains into conventional antibody architectures to overcome intrinsic instability associated with human IgG molecules. One of the primary approaches is complementarity-determining region (CDR) grafting, where antigen-binding loops from human antibodies are transplanted onto highly stable microbial scaffolds. This allows retention of antigen specificity while significantly improving thermal stability and resistance to denaturation [10]. Unlike traditional humanization techniques, microbial scaffold-based grafting provides a structurally rigid framework that minimizes conformational fluctuations and aggregation under stress conditions.

Another widely adopted strategy is domain fusion, in which microbial Ig-like domains are appended to the Fab or Fc regions of monoclonal antibodies. Such fusion constructs enhance solubility and folding efficiency by introducing additional β-sheet interactions that stabilize the overall protein architecture. These engineered constructs have demonstrated improved expression yields and stability in both prokaryotic and eukaryotic expression systems, particularly in cytoplasmic environments where disulfide bond formation is limited [30]. Furthermore, fusion with microbial domains can protect antibodies from proteolytic degradation, especially in protease-rich environments such as inflamed tissues or the gastrointestinal tract [23].

Advances in computational biology have enabled de novo antibody design, where entirely new Ig-like scaffolds are generated using algorithms such as Rosetta and deep learning-based tools [24]. These approaches allow precise control over structural parameters, including β-strand orientation, loop length, and core packing. Designed scaffolds often exhibit superior stability compared to naturally occurring antibodies, with melting temperatures exceeding 90°C and resistance to chaotropic agents. Importantly, these synthetic scaffolds can be tailored to accommodate specific antigen-binding sites, enabling the development of highly customized therapeutic antibodies.

Directed evolution techniques, including phage display and yeast surface display, further refine engineered antibodies by selecting variants with enhanced affinity, specificity, and stability [4]. Large combinatorial libraries incorporating microbial Ig-like domains can be screened under stringent conditions, such as high temperature or low pH, to isolate ultra-stable candidates. This iterative selection process mimics natural evolutionary pressures, resulting in antibodies with optimized biophysical and functional properties.

Fc engineering plays a crucial role in improving the effector functions of monoclonal antibodies. Mutations – such as S239D and I332E – enhance binding to Fcγ receptors, thereby increasing antibody-dependent cellular cytotoxicity (ADCC) [17]. Similarly, modifications that promote hexamer formation on antigen surfaces can enhance complement-dependent cytotoxicity (CDC), improving therapeutic efficacy in oncology and infectious diseases [18]. Glycoengineering, including afucosylation of Fc glycans, further amplifies these effector functions by increasing receptor affinity and immune activation [15].

In addition to stability and effector function enhancement, engineering strategies also focus on improving pharmacokinetics and half-life. Modifications that enhance binding to the neonatal Fc receptor (FcRn) prolong antibody circulation time, reducing dosing frequency and improving patient compliance [15]. Incorporation of microbial Ig-like domains can further stabilize the Fc region, indirectly contributing to improved pharmacokinetic profiles.

Emerging approaches include the development of bispecific and multispecific antibodies, where multiple antigen-binding domains are integrated into a single molecule. Microbial Ig-like scaffolds provide a robust platform for such designs, as their structural stability supports the incorporation of multiple functional domains without compromising overall integrity [20]. These advanced constructs enable simultaneous targeting of multiple pathways, enhancing therapeutic efficacy in complex diseases such as cancer and autoimmune disorders.

Despite these advancements, challenges remain, particularly regarding immunogenicity and structural compatibility. Microbial sequences may introduce non-human epitopes that trigger immune responses. However, computational epitope prediction and sequence humanization strategies can mitigate these risks while preserving stability advantages [10]. Structural compatibility between grafted domains and human antibody frameworks must also be carefully optimized to avoid loss of function or misfolding.

Overall, the integration of microbial Ig-like domains into monoclonal antibody engineering represents a powerful strategy to generate next-generation biologics with enhanced stability, functionality, and manufacturability. By combining rational design, computational modeling, and evolutionary screening, it is now possible to develop ultra-stable antibodies capable of performing under conditions that would inactivate conventional therapeutics.[Table:4]

Table 4. Engineering approaches.

Method	Target	Outcome	Example	References
CDR Grafting	Variable regions	Stability + affinity	KRAS mAbs	[4]
Domain Fusion	Fc/Fab	Solubility	Cytoplasmic antibodies	[10]
De Novo Design	Full scaffold	Novel folds	Ig variants	[24]
Directed Evolution	Combinatorial	Ultra-stability	Long CDR	[10]

PRECLINICAL VALIDATION AND STABILITY ASSAYS

Differential scanning calorimetry (DSC) evaluates thermal stability, while size-exclusion chromatography assesses aggregation. In vivo studies show extended half-life via FcRn recycling [15].

Preclinical validation of engineered ultra-stable monoclonal antibodies (mAbs) requires a comprehensive evaluation of their biophysical stability, structural integrity, functional activity, and pharmacokinetic behavior. Among the most critical parameters is thermal stability, commonly assessed using differential scanning calorimetry (DSC), which provides precise measurements of the melting temperature (Tm) and unfolding transitions of antibody domains. Microbial Ig-like domain integration typically results in significant Tm elevation (often >85–90°C), indicating enhanced resistance to thermal denaturation compared to conventional IgG molecules [30].

In addition to DSC, size-exclusion chromatography (SEC) is extensively used to evaluate aggregation propensity under both native and stress conditions. Aggregation is a major concern in antibody therapeutics, as it can reduce efficacy and increase immunogenicity. Engineered antibodies incorporating microbial domains consistently demonstrate reduced aggregate formation, even at high protein concentrations (>100 mg/mL), highlighting their suitability for high-dose formulations [13]. Complementary techniques – such as dynamic light scattering (DLS) and analytical ultracentrifugation – further characterize particle size distribution and oligomeric states, providing a detailed understanding of protein stability in solution [10].

Chemical stability is assessed using denaturation assays involving chaotropic agents such as urea or guanidinium hydrochloride (GdnHCl). Microbial Ig-like domains confer exceptional resistance to such denaturants, maintaining structural integrity even at high concentrations (>4–5 M GdnHCl), which reflects their tightly packed cores and reduced solvent accessibility [29]. Proteolytic stability is another critical parameter, particularly for therapeutic applications in protease-rich environments. Enzymatic digestion assays using proteases – such as trypsin, chymotrypsin, and HtrA – demonstrate that engineered antibodies exhibit significantly prolonged half-lives compared to native antibodies [23].

Preclinical Validation and Stability Assays

“While differential scanning calorimetry (DSC) and size-exclusion chromatography (SEC) are widely used, they are not definitive standalone indicators of stability.”

DSC Limitations

- Buffer composition significantly alters melting temperature (Tm).
- Cannot distinguish reversible vs irreversible unfolding.
- Poor sensitivity for multi-domain unfolding transitions.

SEC Limitations

- Limited resolution for detecting small oligomers.
- Cannot differentiate reversible vs irreversible aggregation.
- Strong dependence on column conditions and flow rate.

DLS Limitations

- Highly sensitive to dust and impurities.
- Provides averaged size → masks heterogeneity.

Therefore, "a multi-orthogonal analytical approach combining DSC, SEC, DLS, and biophysical assays is essential for reliable stability assessment rather than relying on a single method."

Flowchart Showing – Stability Assessment Pipeline

[Protein Sample]
↓
[DSC → Thermal Stability]
↓
[SEC → Aggregation Profile]
↓
[DLS → Particle Size Distribution]
↓
[Chemical Denaturation Assays]
↓
[Functional Binding Assays (SPR/ELISA)]
↓
[Integrated Stability Conclusion]

Functional validation is equally essential to ensure that enhanced stability does not compromise antigen-binding affinity or specificity. Techniques – such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) – are used to determine binding kinetics, including association (ka), dissociation (kd), and equilibrium dissociation constants (KD). Engineered antibodies often retain nanomolar to picomolar affinity, confirming that structural modifications do not adversely affect antigen recognition [3, 10].

Cell-based assays are employed to evaluate biological activity, particularly for antibodies designed to elicit immune effector functions. Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays measure the ability of engineered antibodies to recruit immune cells and activate complement pathways. Fc-engineered antibodies, especially those with enhanced Fcγ receptor binding, demonstrate significantly improved effector responses in vitro [17, 18].

In vivo preclinical studies provide critical insights into pharmacokinetics (PK), biodistribution, and therapeutic efficacy. Animal models, including human FcRn transgenic mice, are commonly used to evaluate antibody half-life and clearance rates. Enhanced interaction with the neonatal Fc receptor (FcRn) facilitates antibody recycling and protects against lysosomal degradation, leading to extended serum half-life [15]. Engineered ultra-stable antibodies often exhibit prolonged circulation times, reduced dosing frequency, and improved therapeutic outcomes compared to conventional antibodies.

(IN VIVO SECTION IMPROVEMENT – REVIEWER POINT 4)

New Insertion: Species Differences in FcRn

"FcRn binding exhibits significant interspecies variability, with murine FcRn displaying higher affinity for human IgG compared to human FcRn, potentially leading to overestimation of half-life in mouse models."

New Insertion: Transgenic Mouse Limitations

- Incomplete recapitulation of human immune system.
- Altered antibody clearance pathways.
- Limited predictive value for human PK.

New Insertion: Immunogenicity Impact on PK

"Anti-drug antibodies (ADAs) can accelerate clearance, neutralize therapeutic function, and introduce variability in pharmacokinetics, which is often underestimated in preclinical models."[Table:5]

Added Flowchart – In Vivo Translation Gap

[Mouse Model Data]
↓
[FcRn Differences]
↓
[Immune System Variability]
↓
[ADA Formation]
↓
[Altered PK/PD]
↓
[Clinical Outcome Uncertainty]

Table 5. Stability assay benchmarks.

Assay	Gain	Threshold	References
DSC (Tm)	+20°C	>85°C	[10]
Aggregation	<5%	<2%	[15]
Protease resistance	>10×	>24h	[13]
PK half-life	2–4×	>21 days	[29, 30]

THERAPEUTIC APPLICATIONS

Ultra-stable mAbs target oncology, infectious diseases, and autoimmune disorders [10, 14].

In oncology, ultra-stable monoclonal antibodies are being developed to target tumor-associated antigens and immune checkpoints, offering improved efficacy through enhanced persistence and reduced aggregation. Stability improvements enable higher dosing concentrations and prolonged circulation, which are critical for targeting solid tumors and resistant cancer pathways such as KRAS and HER2 [10]. Additionally, Fc-engineered antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) further improve anti-tumor responses [17, 18].

In infectious diseases, ultra-stable mAbs provide advantages in targeting multidrug-resistant pathogens and virulence factors. Their resistance to proteolytic degradation allows effective functioning in hostile environments, such as inflamed tissues or mucosal surfaces. Antibodies targeting bacterial adhesins, toxins, or viral proteins demonstrate improved durability and broader therapeutic coverage [8, 14].

For autoimmune disorders, engineered antibodies targeting cytokines, such as IL-6 or TNF-α, benefit from extended half-life and reduced dosing frequency, improving patient compliance and treatment outcomes [12]. Enhanced stability also supports subcutaneous formulations at high concentrations, which are increasingly preferred in chronic disease management [13].

Emerging applications include bispecific and multispecific antibodies, which simultaneously target multiple pathways. Microbial Ig-like scaffolds provide the structural robustness required to maintain functionality in such complex formats [20]. Furthermore, ultra-stable antibodies are being explored for neurological diseases, where improved stability may support better blood–brain barrier penetration and sustained therapeutic action.

Overall, the integration of microbial Ig-like domains expands the therapeutic scope of monoclonal antibodies by improving stability, efficacy, and versatility across a wide range of clinical indications [10, 14].[Table:6]

Table 6. Application domains.

Indication	Candidate	Advantage	Phase	References
Cancer	KRAS-targeting mAbs	Stability	Preclinical	[10]
Infection	CEACAM-binding	Broad-spectrum	Preclinical	[12]
Autoimmune	IL-6 inhibitors	Long half-life	IND	[14]
Neuro	Amyloid targeting	BBB penetration	Discovery	[10]

MANUFACTURING AND SCALABILITY

Microbial scaffolds reduce reliance on glycosylation, enabling alternative expression systems such as *Pichia pastoris* [13].

The incorporation of microbial Ig-like domains into monoclonal antibodies significantly improves manufacturing efficiency and scalability, primarily by reducing dependence on complex post-translational modifications such as glycosylation. Traditional antibody production relies heavily on mammalian cell systems, particularly Chinese hamster ovary (CHO) cells, which are costly and require stringent culture conditions [13]. In contrast, engineered antibodies with microbial scaffolds can be effectively expressed in alternative hosts, including yeast and bacterial systems, without compromising structural stability or functionality.

Expression systems – such as *Pichia pastoris* – offer several advantages, including high protein yield, rapid growth, and cost-effective large-scale fermentation. These systems are particularly suitable for producing stable antibody fragments or fusion constructs that do not require extensive glycosylation [13]. Similarly, *Escherichia coli* expression enables rapid and economical production, especially for cytoplasmic antibodies engineered to function without disulfide bonds [30].

Scalability is further enhanced by the improved intrinsic stability of engineered antibodies, which reduces aggregation during production, purification, and storage. This stability allows higher expression titers and simplifies downstream processing steps such as filtration and chromatography [10]. Moreover, reduced aggregation minimizes product loss and improves batch consistency, which is critical for regulatory approval and commercial manufacturing.

Advances in bioprocess optimization, including fed-batch and continuous perfusion systems, further support large-scale production of ultra-stable antibodies. These systems can achieve high volumetric productivity while maintaining product quality and stability [13]. Additionally, the robustness of microbial Ig-like domains enables tolerance to process-related stresses such as fluctuations, shear forces, and pH variations.

Flowchart Showing – Clinical Translation Bottlenecks

Overall, metagenome-informed antibody engineering facilitates the transition from traditional mammalian expression systems to more cost-effective, scalable, and flexible production platforms, thereby enhancing the feasibility of widespread therapeutic deployment [13, 30].[Table:7]

Table 7. Production platforms.

Host	Yield (g/L)	Cost	Stability	References
CHO	5–10	High	Baseline	[10]
Pichia	10–20	Medium	High	[13]
E. coli	2–5	Low	Ultra	[30]
Plant	1–3	Low	Moderate	[13]

CHALLENGES AND IMMUNOGENICITY

Immunogenicity remains a key concern. Humanization strategies reduce T-cell epitope recognition [10].

Despite the advantages of microbial Ig-like domains, their non-human origin introduces the risk of eliciting anti-drug antibodies (ADAs), which can reduce therapeutic efficacy and alter pharmacokinetics [10]. Immunogenic responses are primarily driven by the presence of foreign T-cell epitopes that are recognized by the host immune system, leading to neutralization or rapid clearance of the therapeutic antibody.

To address this, humanization and de-immunization strategies are widely employed. These include sequence alignment and back-mutation approaches, where non-human residues are replaced with human germline counterparts while preserving structural integrity and stability [10]. In silico tools are also used to predict and eliminate potential T-cell epitopes, thereby minimizing immune recognition without compromising function.

Another challenge is maintaining structural compatibility between microbial domains and human antibody frameworks. Improper integration may lead to misfolding, reduced binding affinity, or loss of effector functions. Careful optimization through computational modeling and experimental validation is, therefore, essential to ensure correct folding and functional performance [24].

Additionally, off-target binding and cross-reactivity can arise due to structural modifications. These risks are mitigated through affinity maturation techniques, such as phage display, which refine antigen specificity under selective conditions [4]. Stability-enhancing modifications must also be balanced against functional requirements to avoid compromising antigen recognition.

From a regulatory perspective, engineered antibodies incorporating microbial components must undergo rigorous evaluation for safety, immunogenicity, and comparability with existing biologics. Regulatory agencies require detailed characterization of structural modifications, stability profiles, and immune responses before clinical approval [11].

Overall, while challenges related to immunogenicity and structural integration persist, advances in computational design, humanization techniques, and high-throughput screening are enabling the development of safe and effective ultra-stable monoclonal antibodies [10, 24].[Table:8]

Table 8. Risk mitigation strategies.

Challenge	Solution	References
Immunogenicity	Humanization	[4]
Off-target effects	Affinity maturation	[10]
Stability trade-offs	Optimization	[11]
Regulatory hurdles	Comparability studies	[24]

CLINICAL TRANSLATION ROADMAP

Clinical translation involves multi-phase evaluation of safety, efficacy, and pharmacokinetics [11].

The clinical development of ultra-stable monoclonal antibodies follows a structured pipeline beginning with lead optimization and preclinical validation, where candidates are assessed for stability, binding affinity, and safety profiles. Following this, Investigational New Drug (IND)-enabling studies are conducted to evaluate toxicity, pharmacokinetics, and manufacturability under regulatory guidelines [11].

Phase I clinical trials primarily focus on safety, tolerability, and dose escalation in a small cohort of healthy volunteers or patients. Phase II trials assess therapeutic efficacy and optimal dosing, while Phase III trials involve large-scale validation of clinical benefit compared to standard treatments. Engineered ultra-stable antibodies may offer advantages, such as reduced dosing frequency and improved patient compliance, due to extended half-life [15].

Critical Challenges in Clinical Translation

Immunogenicity of Microbial Domains

- Non-human sequences → T-cell epitope activation.
- Risk of neutralizing antibodies.
- Requires de-immunization + in silico epitope mapping.

Manufacturing Scalability Issues

- Folding incompatibility in CHO systems.
- Aggregation in high-expression systems.
- Batch-to-batch variability concerns.

Expression System Compatibility

- Microbial domains may misfold in mammalian cells.
- Lack of glycosylation may affect stability/effector function.
- Trade-off between cost vs functionalities.

Regulatory Uncertainty

- Lack of defined guidelines for non-canonical scaffolds.
- Comparability with conventional mAbs unclear.
- Increased regulatory scrutiny required.

Regulatory approval requires comprehensive documentation of quality, safety, and efficacy, including comparability studies with existing biologics and detailed characterization of structural modifications [11]. The enhanced stability of microbial Ig-like domain-based antibodies may simplify storage and distribution requirements, particularly in resource-limited settings.[Table:9]

Flowchart Showing – Entire Pipeline

[Metagenomic Mining]
↓
[Ig-like Domain Identification]
↓
[Structural Characterization]
↓
[Antibody Engineering]
↓
[Stability Optimization]
↓
[Preclinical Validation]

↓
[In Vivo Testing]
↓
[Clinical Development]
↓
[Therapeutic Deployment]

Table 9. Development timeline.

Stage	Duration (years)	References
Discovery	1–2	[11]
Preclinical	2–3	[11]
Clinical trials	3–5	[11]
Approval	6–8	[11]

FUTURE DIRECTIONS

Integration of artificial intelligence with metagenomics will accelerate antibody design. Tools – such as deep learning-based protein modelling – will enable precise scaffold engineering [24]. Hybrid human-microbial antibodies may redefine therapeutic stability, reduce cost and improving global accessibility.

Future advancements are expected to arise from the convergence of metagenomics, synthetic biology, and artificial intelligence. Deep learning frameworks – such as protein structure prediction and generative design models – can rapidly identify and optimize microbial Ig-like domains with desired stability and functional properties [24]. These approaches enable the design of tailor-made antibody scaffolds with enhanced precision and reduced experimental workload.

Emerging technologies – such as RFdiffusion and large protein language models – are likely to revolutionize de novo antibody design, enabling the creation of novel folds not found in nature. Additionally, integration with high-throughput screening platforms and automated biofoundries will accelerate the discovery-to-clinic pipeline.

The development of hybrid human-microbial chimeric antibodies represents a promising direction, combining the low immunogenicity of human sequences with the exceptional stability of microbial domains. Such constructs may enable the production of next-generation biologics with improved shelf life, reduced cold-chain dependence, and broader global accessibility, particularly in low-resource settings [13].

CONCLUSION

Metagenome-informed engineering represents a transformative approach in antibody therapeutics. By leveraging microbial Ig-like domains, researchers can overcome fundamental limitations of conventional monoclonal antibodies. This strategy holds promise for developing ultra-stable, cost-effective, and highly efficacious biologics across diverse disease areas.

In addition, the integration of advanced computational tools, innovative engineering strategies, and scalable manufacturing platforms positions this approach as a key driver of future biopharmaceutical innovation. As challenges related to immunogenicity and regulatory approval continue to be addressed, metagenome-informed antibody design is expected to play a central role in shaping the next generation of therapeutic proteins [10, 24].

REFERENCES

1. Saeed AFUH, Wang R, Ling S, Wang S. Antibody engineering for pursuing a healthier future. Front Microbiol. 2017;8:495.
2. Vacca F, Sala C, Rappuoli R. Monoclonal antibodies for bacterial pathogens: Mechanisms of action and engineering approaches for enhanced effector functions. Biomedicines. 2022;10(9):2126.

3. Hnasko TS, Stanker LH. ELISA: Methods and protocols. Methods Mol Biol. 2015;1318:1–5.
4. Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. mAbs. 2013;5(4):622–627.
5. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
6. Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 2021;42(12):1143–1155.
7. Luciani M, Iannetti L. Monoclonal antibodies and bacterial virulence. Virulence. 2017;8(1):635–636.
8. Speziale P, Pietrocola G. Monoclonal antibodies targeting surface-exposed and secreted proteins from staphylococci. Vaccines (Basel). 2021;9(5):459.
9. Ojima-Kato T, Morishita S, Uchida Y, Nagai S, Kojima T, Nakano H. Rapid generation of monoclonal antibodies from single B cells by Ecobody technology. Antibodies (Basel). 2018;7(4):38.
10. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front Immunol. 2018;8:1751.
11. Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–495.
12. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(4):e00535.
13. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9–14.
14. Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: Antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61.
15. Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296.
16. van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548.
17. Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest. 2014;124(2):725–729.
18. Kang TH, Jung ST. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp Mol Med. 2019;51:1–9.
19. Mimoto F, Kuramochi T, Katada H, Igawa T, Hattori K. Fc engineering to improve the function of therapeutic antibodies. Curr Pharm Biotechnol. 2016;17(13):1298–1314.
20. Jefferis R. Posttranslational Modifications and the Immunogenicity of Biotherapeutics. Journal of Immunology Research. 2016;2016:1–15.
21. Fraser JS, Maxwell KL, Davidson AR. Immunoglobulin-like domains on bacteriophage: weapons of modest damage? Current Opinion in Microbiology. 2007 Aug;10(4):382–7. Available from: https://pubmed.ncbi.nlm.nih.gov/17765600/
22. Bodelón G, Palomino C, Fernández LÁ. Immunoglobulin domains inEscherichia coliand other enterobacteria: from pathogenesis to applications in antibody technologies. FEMS Microbiology Reviews. 2013 Mar;37(2):204–50. Available from: https://pubmed.ncbi.nlm.nih.gov/22724448/ .
23. 1. Bodelón G, Palomino C, Fernández LÁ. Immunoglobulin domains inEscherichia coliand other enterobacteria: from pathogenesis to applications in antibody technologies. FEMS Microbiology Reviews. 2013 Mar;37(2):204–50. Available from: https://www.researchgate.net/publication/228058912_Immunoglobulin_domains_inEscherichia_coliand_other_enterobacteria_from_pathogenesis_to_applications_in_antibody_technologies
24. Chidyausiku TM, Mendes SR, Klima JC, Nadal M, Eckhard U, Roel-Touris J, et al. De novo design of immunoglobulin-like domains. Nature Communications. 2022 Oct 3;13(1). Available from: https://pubmed.ncbi.nlm.nih.gov/36192397/
25. Xian F, Brenek M, Krisp C, Urbauer E, Ravi Kumar RK, Aguanno D, et al. Ultra-sensitive metaproteomics redefines the dark metaproteome, uncovering host-microbiome interactions and drug targets in intestinal diseases. Nature Communications. 2025 July 18;16(1). Available from: https://pubmed.ncbi.nlm.nih.gov/40681571/

26. Olm MR, Spencer SP, Takeuchi T, Silva EL, Sonnenburg JL. Metagenomic immunoglobulin sequencing reveals IgA coating of microbial strains in the healthy human gut. Nature Microbiology. 2025 Jan 2;10(1):112–25. Available from: https://pubmed.ncbi.nlm.nih.gov/39747692/
27. Simeon N, Nicolas P, Christophe P, Martin L, Agnes R, Yannick M, Vicart S, Elisabeth M, Caroline P, Guy G, Lejla I. Functional Immuno-metagenomics Seizes the Alteration of Microbiota-Immune Interactions at the Early Onset of Multiple Sclerosis. bioRxiv. 2026 Jan 13:2026-01.
28. 1. Maranga M, Szczerbiak P, Bezshapkin V, Gligorijevic V, Chandler C, Bonneau R, et al. Comprehensive Functional Annotation of Metagenomes and Microbial Genomes Using a Deep Learning-Based Method. Sharpton TJ, editor. mSystems [Internet]. 2023 Apr 27 [cited 2026 Sept 11];8(2). Available from: https://pubmed.ncbi.nlm.nih.gov/37010293/
29. van Sorge NM, Bonsor DA, Deng L, Lindahl E, Schmitt V, Lyndin M, Schmidt A, Nilsson OR, Brizuela J, Boero E, Sundberg EJ. Bacterial protein domains with a novel Ig-like fold target human CEACAM receptors. The EMBO Journal. 2021 Apr 1;40(7):EMBJ2020106103.
30. Kabayama H, Takeuchi M, Tokushige N, Muramatsu SI, Kabayama M, Fukuda M, Yamada Y, Mikoshiba K. An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nature communications. 2020 Jan 17;11(1):336..
31. Sormanni P, Aprile FA, Vendruscolo M. The capsid claw of adeno-associated virus binds to the viral protein VP3. J Biol Chem. 2015;290(12):7328–7338.
32. DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, et al. Identification of broadly protective human antibodies toPseudomonas aeruginosaexopolysaccharide Psl by phenotypic screening. Journal of Experimental Medicine. 2012 June 25;209(7):1273–87. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3405507/
33. Rothwell RS, Davis P, Gordon PA, Dasgupta MK, Johny KV, Russell AS, et al. A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis & Rheumatism. 1980 July ;23(7):785–90. Available from: https://pubmed.ncbi.nlm.nih.gov/7406929/ .
34. Hüttener M, Hergueta J, Bernabeu M, Prieto A, Aznar S, Merino S, et al. Roles of Proteins Containing Immunoglobulin-Like Domains in the Conjugation of Bacterial Plasmids. Ellermeier CD, editor. mSphere. 2022 Feb 23;7(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8730810/
35. Tkaczyk C, Hamilton MM, Sadowska A, Shi Y, Chang CS, Chowdhury P, et al. Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease. Drusano GL, editor. mBio. 2016 July 6;7(3). Available from: https://pubmed.ncbi.nlm.nih.gov/27353753/
36. Ward ME, Glynn AA. Human antibody response to lipopolysaccharides from Neisseria gonorrhoeae. Journal of Clinical Pathology. 1972 Jan;25(1):56–9. Available from: https://pubmed.ncbi.nlm.nih.gov/4622625/
37. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Science Translational Medicine. 2014 Nov 12;6(262). Available from: https://pubmed.ncbi.nlm.nih.gov/25391481/
38. Checking your browser - reCAPTCHA. Nih.gov. 2026. Available from: https://www.google.com/recaptcha/challengepage
39. Petrova E, Kiriako G, Rebetz J, Johansson K, Wennmalm S, Meijer NEJ, et al. Engineering multivalent Fc display for FcγR blockade. 2024 Jan 23;. Available from: https://www.biorxiv.org/content/10.1101/2024.01.20.576357v1 .

